Top

Published in:

01-09-2008 | Review

Current management of DCIS: a review

Authors: Neill Patani, Bruno Cutuli, Kefah Mokbel

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Ductal carcinoma in-situ (DCIS) is a heterogeneous disease, in terms of its radiological characteristics, histological morphology and molecular attributes. This diversity is reflected in its natural history and influences optimal treatment strategy. A significant proportion of DCIS lesions behave in a clinically benign fashion and do not progress to invasive disease. Reliable identification of these patients could allow treatment to be less radical or safely omitted. Management should be tailored to the individual within the context of a multidisciplinary team. Approaches such as biological profiling and molecular analysis represent an opportunity to improve our understanding of the tumour biology of this condition and rationalise its treatment. This article reviews the management strategies for DCIS in the context of recent randomized trials, including the role of sentinel lymph node biopsy, adjuvant radiotherapy and tamoxifen.

Lippman M (2002) Why study ductal carcinoma in-situ? In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott, William and Wilkins, Philadelphia pp 12–16

Netter E, Troufleau P, Stines J (1998) Ductal carcinoma in-situ of the breast: role of imaging. J Radiol 79:651–658PubMed

Sumner WE 3rd, Koniaris LG, Snell SE, Spector S, Powell J, Avisar E, Moffat F, Livingstone AS, Franceschi D (2007) Results of 23,810 cases of ductal carcinoma-in-situ. Ann Surg Oncol 14(5):1638–1643PubMedCrossRef

Ernster VL, Barclay J (1997) Increases in ductal carcinoma in-situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 22:151–156PubMed

Bobo JK, Lee NC, Thames SF (2000) Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 92:971-976PubMedCrossRef

Pisano E, Gatsonia C, Hendrick E et al (2005) Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening. NEJM 353:1773–1783PubMedCrossRef

Boetes C, Veltman J (2005) Screening women at increased risk with MRI. Cancer Imaging 23(suppl 5):S10–S15CrossRef

Menell JH, Morris EA, Dershaw DD, Abramson AF, Brogi E, Liberman L (2005) Determination of the presence and extent of pure ductal carcinoma in-situ by mammography and magnetic resonance imaging. Breast J 11(6):382–390PubMedCrossRef

Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH (2007) MRI for diagnosis of pure ductal carcinoma in-situ: a prospective observational study. Lancet 370(9586):485–492PubMedCrossRef

10.

Mokbel K, Escobar PF, Matsunaga T (2005) Mammary ductoscopy: current status and future prospects. Eur J Surg Oncol 31:3–8PubMedCrossRef

11.

Going JJ, Moffat DF (2004) Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J Pathol 203(1):538–544PubMedCrossRef

12.

Zhao L, Freimanis R, Bergman S et al (2003) Biopsy needle technique and the accuracy of diagnosis of atypical ductal hyperplasia for mammographic abnormalities. Am Surg 69:757–762PubMed

13.

Douglas-Jones AG, Gupta SK, Attanoos RL, Morgan JM, Mansel RE (1996) A critical appraisal of six modern classifications of ductal carcinoma in-situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 29:397–409PubMedCrossRef

14.

Douglas-Jones AGM, Morgan J, Appleton MAC et al (2000) Consistency in the observation of features used to classify duct carcinoma in-situ. J Clin Pathol 53:596–602PubMedCrossRef

15.

Badve S, A’Hern RP, Ward AM et al (1998) Prediction of local recurrence of ductal carcinoma of the breast using five histological classifications. A comparative study with long follow-up. Hum Pathol 29:915–923PubMedCrossRef

16.

Bethwaite P, Smith N, Delahunt B, Kenwright D (1998) Reproducibility of new classification schemes for the pathology of ductal carcinoma in-situ of the breast. J Clin Pathol 5:450–454

17.

Betsill WL, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239:1863–1867PubMedCrossRef

18.

Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in-situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103:2481–2484PubMedCrossRef

19.

Leonard GD, Swain SM (2004) Ductal carcinoma in-situ, complexities and challenges. J Natl Cancer Inst 96:906–920PubMed

20.

Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in-situ treated by lumpectomy. J Natl Cancer Inst 95:1692–1702PubMed

21.

Bijker N, Peterse JL, Duchateau L et al (2001) Risk factor for recurrence and metastasis after breast conserving therapy for ductal carcinoma in-situ: analysis of European Organisation for Research and Treatment of Cancer trial 10853. J Clin Oncol 19(8):2263–2271PubMed

22.

Nakhlis F, Morrow M (2003) Ductal carcinoma in-situ. Surg Clin North Am 83:821–839PubMedCrossRef

23.

Ben-David MA, Sturtz DE, Griffith KA, Douglas KR, Hayman JA, Lichter AS, Pierce LJ (2007) Long-term results of conservative surgery and radiotherapy for ductal carcinoma in-situ using lung density correction: the University of Michigan experience. Breast J 13(4):392–400PubMedCrossRef

24.

Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2007 Aug 9; [Epub ahead of print]. PMID: 17687650

25.

Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma in-situ of the breast: a critical review of the literature. J Clin Oncol 20:2736–2744PubMedCrossRef

26.

Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in-situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28:400–418PubMedCrossRef

27.

Fourquet A, Zigal-zafrani B, Clough KB (2002) Breast-conserving surgery plus radiation therapy in ductal carcinoma in-situ: the Institut Curie experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia, pp 367–372

28.

Solin LJ, Fourquet A, Vicini F et al (2001) Mammographically detected ductal carcinoma in-situ of the breast treated with breast-conserving surgery and definitive breast irradiation long-term outcome and prognostic significance of patient age and margin status. Int J Radiot Oncol Biol Phys 50:991–1102CrossRef

29.

Solin L, Fourquet A, Vicini F et al (2005) Long-term outcome after breast conservation treatment with radiation for mammographically detected ductal carcinoma in-situ of the breast. Cancer 1003:1137–1146CrossRef

30.

Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA (2000) Carcinoma in-situ of the female breast. 10-year follow-up results of a prospective nation-wide study. Breast Cancer Res Treat 62:197–210PubMedCrossRef

31.

Cutuli B, Cohen Solal Le Nir C, De Lafontan B et al (2002) Breast conserving therapy for ductal carcinoma in-situ of the breast: the French Cancer centers’ experience. Int J Radiat Oncol Biol Phys 53:868–879PubMed

32.

Schwartz GF, Solin LJ, Olivotto IA et al (2000) Consensus conference on the treatment of in-situ ductal carcinoma of the breast, April 22–25,1999. Cancer 88:946–954PubMedCrossRef

33.

Mac Donald HR, Silverstein MJ, Mabry H et al (2005) Local control in ductal carcinoma in-situ treated by excision alone: incremental benefit of larger margins. Am J Surg 190:521–525CrossRef

34.

Schouten van der Velden AP, van Vugt R, Van Dijck JA, Leer JW, Wobbes T (2007) Local recurrences after different treatment strategies for ductal carcinoma in-situ of the breast: a population-based study in the East Netherlands. Int J Radiat Oncol Biol Phys [Epub ahead of print]

35.

Morrow M, Strom E, Basset LW et al (2002) Standard for the management of ductal carcinoma in-situ of the breast. Cancer J Clin 52:256–276CrossRef

36.

Silverstein MJ (2002) Margin width as the sole predictor of local recurrence in patients with ductal carcinoma in-situ of the breast. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia, pp 482–493

37.

Neuschatz AC, Di Petrillo T, Steinhoff M et al (2002) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in-situ of the breast. Cancer 94:1917–1924PubMedCrossRef

38.

Cutuli B, Fourquet A, Luporsi E et al (2004) Standards, Options et Recommandations. Prise en charge des carcinomes canalaires in-situ du sein. www.fnclcc.fr

39.

Park C, Schmitt J, Recht A (2002) Joint Center for radiation therapy experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia, pp 373–380

40.

Lagios MD (2002) The Lagios experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott, William and Wilkins, Philadelphia, pp 303–307

41.

Silverstein MJ, Poller DN, Waisman JR et al (1995) Prognostic classification of breast ductal carcinoma in-situ. Lancet 345:1154–1157PubMedCrossRef

42.

Lagios MD, Silverstein MJ (1997) Ductal carcinoma in-situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomised prospective studies. Surg Oncol Clin North Am 6:385–392

43.

Holland R, Peterse JL, Millis RR et al (1994) Ductal carcinoma in-situ: a proposal for a new classification. Semin Diagn Pathol 11:167–180PubMed

44.

Idvall I, Anderson H, Ringberg A, Ferno M (2003) Are cellular polarisation and mitotic frequency prognostic factors for local recurrence in patients with ductal carcinoma in-situ of the breast? Eur J Cancer 39:1704–1710PubMedCrossRef

45.

Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in-situ of the breast. Am J Surg 186:337–343PubMedCrossRef

46.

Silverstein MJ, Poller DN, Craig P et al (1996) A prognostic index for ductal carcinoma in-situ of the breast classification. Cancer 77:2267–2274PubMedCrossRef

47.

Silverstein MJ, Buchanan C (2003) Ductal carcinoma in-situ: USC/VAN NUYS prognostic index and the impact of margin status. The Breast 12:457–471PubMedCrossRef

48.

Cutuli B, Lemanski C, Cohen-Solal C et al (2003) Ductal carcinoma in-situ (DCIS) of the breast: what is the safest treatment? Int J Rad Oncol Biol Phys 57(suppl 2):S361

49.

Baqai T, Shousha S (2003) Oestrogen receptor negativity as a marker for high grade ductal carcinoma in-situ of the breast. Histopathology 42:440–447PubMedCrossRef

50.

Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE (2003) Biological markers that predict recurrence in ductal carcinoma in-situ of the breast. Eur J Cancer 39:622–630PubMedCrossRef

51.

Buerger H, Otterbach F, Simon R et al (1999) Comparative genomic hybridization of ductal carcinoma in-situ of the breast—evidence of multiple genetic pathways. J Pathol 187:396–402PubMedCrossRef

52.

Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Welzl G, Hofler H, Werner M (2000) Extensive ductal carcinoma in-situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 85:82–86PubMedCrossRef

53.

Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ (2006) Classification of ductal carcinoma in-situ by gene expression profiling. Breast Cancer Res 8(5):R61PubMedCrossRef

54.

Wulfkuhle JD, Sgroi DC, Krutzsch H et al (2002) Proteomics of human breast ductal carcinoma in-situ. Cancer Res 62:6740–6749PubMed

55.

Gotte M, Kersting C, Radke I, Kiesel L, Wulfing P (2007) An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in-situ. Breast Cancer Res 9(1):R8PubMedCrossRef

56.

Boyages J, Delaney G, Taylor R (1999) Predictors of local recurrence after treatment of ductal carcinoma in-situ. A meta-analysis. Cancer 85:616–628PubMedCrossRef

57.

Douek M, Baum M (2003) Mass breast screening: is there a hidden cost? Br J Surg 90(suppl 1), June: (Abstract Breast 14)

58.

Baxter N, Virnig BA, Durham JB, Tuttle TM (2004) Trend in treatment of ductal carcinoma in-situ of the breast. Natl Cancer Inst 96:443–448CrossRef

59.

Kricker A, Amstrong B (2004) Surgery and outcome of ductal carcinoma in-situ of the breast: a population-based study in Australia. Eur J Cancer 40:2396–2402PubMedCrossRef

60.

Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in-situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958PubMedCrossRef

61.

Cutuli B, Lemanski C, Fourquet A et al (2005) French National Survey on DCIS: analysis of clinico-pathological features and treatments in 1289 patients. Eur J Cancer 3(suppl 2):77, Abs 274

62.

Cunnick GH, Mokbel K (2004) Skin-sparing mastectomy. Am J Surg 188:78–84PubMedCrossRef

63.

Ringberg A, Idvall I, Ferno M et al (2000) Ipslitateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in-situ of the breast. Eur J Surg Oncol 26:444–451PubMedCrossRef

64.

Cataliotti L, Distante V, Orzalesi L, Bianchi S, Ciatto S, Simoncini R et al (2002) The florence experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia pp 348–353

65.

Tunon de Lara C, De Mascarel I, Mac Grogan G et al (2001) Analysis of 676 ductal carcinoma in-situ (DCIS) of the breast from 1971 to 1995: diagnosis and treatment; the experience of one institute. Am J Clin Oncol 24:531–536CrossRef

66.

Cutuli B, Lemanski C, Le Blanc M et al (2002) Local recurrences after DCIS therapy: diagnosis, treatment and outcome. Breast Cancer Res Treat 76(suppl 1):S36, Abs 31

67.

Schwartz GF (2002) Treatment of subclinical ductal carcinoma in-situ of the breast by local excision and surveillance: an update personal experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia, pp 308–321

68.

Arnesson LG, Olsen K (1997) Linköping experience. In: Silverstein MJ (eds) Ductal carcinoma in-situ of the breast. Williams and Wilkins, Baltimore pp 373–377

69.

Wong JS, Gado MA, Gelman C et al (2003) Wide excision alone for ductal carcinoma in-situ (DCIS) of the breast. Proc Am Soc Clin Oncol 22:12, Abs 44

70.

Silverstein MJ (2003) An argument against routine use of radiotherapy for ductal carcinoma in-situ. Oncology 17:1–23

71.

Bijker N, Meijnen PH, Bogaerts J, Peterse JL (2005) Radiotherapy in breast conserving treatment for ductal carcinoma in-situ (DCIS): Ten year results of European Organization for research and Treatment of Cancer (EORTC) randomized trial 10853. Breast Cancer Res Treat 94(suppl 1):s57

72.

UK Coordinating committee on Cancer Research (UKCCCR) (2003) Ductal carcinoma in-situ working party radiotherapy and tamoxifen in women with completely excised ductal carcinoma in-situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102CrossRef

73.

Viani GA, Stefano EJ, Afonso SL, De Fendi LI, Soares FV, Leon PG, Guimaraes FS (2007) Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in-situ: a meta-analysis of randomized trials. Radiat Oncol 2(1):28PubMedCrossRef

74.

Fowble B (2002) Overview of conservative surgery and radiation therapy: ductal carcinoma in-situ. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott, William and Wilkins, Philadelphia, pp 287–302

75.

Warren JL, Weaver DL, Bocklage T et al (2005) The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS. A population-based analysis. Cancer 104:1840–1848PubMedCrossRef

76.

Yerushalmi R, Sulkes A, Mishaeli M, Neumann A, Dinerman M, Sulkes J, Rizel S, Yarom N, Gutman H, Fenig E (2006) Radiation treatment for ductal carcinoma in-situ (DCIS): is a boost to the tumor bed necessary? Neoplasma 53(6):507–510PubMed

77.

Vaidya JS (2007) Partial breast irradiation using targeted intraoperative radiotherapy (Targit). Nat Clin Pract Oncol 4(7):384–385PubMedCrossRef

78.

Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 353:1993–2000PubMedCrossRef

79.

Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2002) Prevention of invasive breast cancer in women with ductal carcinoma in-situ: an update of the national surgical adjuvant breast and bowel project experience. In: Silverstein MJ, Recht A, Lagios M (eds) Ductal carcinoma in-situ of the breast, 2nd edn. Lippincott William and Wilkins, Philadelphia, pp 432–446

80.

Allred DC, Bryant J, Lano S et al (2002) Estrogen receptor expression as a predictive marker of the effectiveness of Tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res Treat 76(suppl 1):536, Abs 30

81.

Mokbel K, Cutuli B (2006) Heterogeneity of ductal carcinoma in-situ and its effects on management. Lancet Oncol 7:756–765PubMedCrossRef

82.

Veronesi P, Intra M, Vento AR et al (2005) Sentinel node biopsy for localised ductal carcinoma in-situ? Breast 14:520–522PubMedCrossRef

83.

Julian TB, Land SR, Fourchotte V, Haile SR, Fisher ER, Mamounas EP, Costantino JP, Wolmark N (2007) Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol 14(8):2202–2208PubMedCrossRef

84.

Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ et al (1998) Outcome after invasive local recurrence inpatients with ductal carcinoma in-situ of the breast. J Clin Oncol 16:1367–1373PubMed

85.

Cutuli B, Lemanski C, Le Blanc-Onfroy M et al. DCIS local recurrence: diagnosis, treatment modalities and long-term outcome. Analysis of 195 cases. Unpublished—Personal communication

86.

Solin L, Fourquet A, Vicini F et al (2005) Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in-situ. Eur J Cancer 41:1715–1723PubMedCrossRef

87.

Cutuli B, Borel C, Dhermain F et al (2001) Breast cancer occurred after treatment for Hodgkin’s disease: analysis of 133 cases. Radiother Oncol 59:247–255PubMedCrossRef

88.

Cutuli B, Dilhuydy JM, De Lafontan B et al (1997) Ductal carcinoma in-situ of the male breast: analysis of 31 cases. Eur J Cancer 33:35–38PubMedCrossRef

89.

Hittmair AP, Lininger RA, Tavassoli FA (1998) Ductal carcinoma in-situ (DCIS) in the male breast. A morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma: a preliminary report. Cancer 83:2139–2149PubMedCrossRef

Title: Current management of DCIS: a review
Authors: Neill Patani
Bruno Cutuli
Kefah Mokbel
Publication date: 01-09-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9760-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan

Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer

The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study

Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast

Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer

Association of polymorphisms of angiogenesis genes with breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer